1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017

BACKGROUND: Ceftolozane–tazobactam (C-T) is an antibacterial combination of a novel antipseudomonal cephalosporin and a β-lactamase inhibitor. C-T was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 to treat complicated urinary tract infections, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Arends, S J Ryan, Shortridge, Dee, Castanheira, Mariana, Streit, Jennifer M, Flamm, Robert K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255016/
http://dx.doi.org/10.1093/ofid/ofy210.884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255016/
http://dx.doi.org/10.1093/ofid/ofy210.884

Ejemplares similares